ADC Repeatability Limits for Oncology Trial Endpoints
Clinical Research & Biomarkers

ADC Repeatability Limits for Oncology Trial Endpoints

When a clinical trial designates the apparent diffusion coefficient — the ADC derived from diffusion-weighted MRI — as a primary or secondary endpoint, it is placing an enormous amount of trust in a…

September 07, 2026 · 10 min read

Fresh in the feed

About

Bridging neuroimaging software and clinical practice.